dc.contributor.author | Richardson, SJ | |
dc.contributor.author | Rodriguez-Calvo, T | |
dc.contributor.author | Gerling, IC | |
dc.contributor.author | Mathews, CE | |
dc.contributor.author | Kaddis, JS | |
dc.contributor.author | Russell, MA | |
dc.contributor.author | Zeissler, M | |
dc.contributor.author | Leete, P | |
dc.contributor.author | Krogvold, L | |
dc.contributor.author | Dahl-Jørgensen, K | |
dc.contributor.author | von Herrath, M | |
dc.contributor.author | Pugliese, A | |
dc.contributor.author | Atkinson, MA | |
dc.contributor.author | Morgan, NG | |
dc.date.accessioned | 2016-08-16T11:00:23Z | |
dc.date.issued | 2016-08-09 | |
dc.description.abstract | AIMS/HYPOTHESIS: Human pancreatic beta cells may be complicit in their own demise in type 1 diabetes, but how this occurs remains unclear. One potentially contributing factor is hyperexpression of HLA class I antigens. This was first described approximately 30 years ago, but has never been fully characterised and was recently challenged as artefactual. Therefore, we investigated HLA class I expression at the protein and RNA levels in pancreases from three cohorts of patients with type 1 diabetes. The principal aims were to consider whether HLA class I hyperexpression is artefactual and, if not, to determine the factors driving it. METHODS: Pancreas samples from type 1 diabetes patients with residual insulin-containing islets (n = 26) from the Network for Pancreatic Organ donors with Diabetes (nPOD), Diabetes Virus Detection study (DiViD) and UK recent-onset type 1 diabetes collections were immunostained for HLA class I isoforms, signal transducer and activator of transcription 1 (STAT1), NLR family CARD domain containing 5 (NLRC5) and islet hormones. RNA was extracted from islets isolated by laser-capture microdissection from nPOD and DiViD samples and analysed using gene-expression arrays. RESULTS: Hyperexpression of HLA class I was observed in the insulin-containing islets of type 1 diabetes patients from all three tissue collections, and was confirmed at both the RNA and protein levels. The expression of β2-microglobulin (a second component required for the generation of functional HLA class I complexes) was also elevated. Both 'classical' HLA class I isoforms (i.e. HLA-ABC) as well as a 'non-classical' HLA molecule, HLA-F, were hyperexpressed in insulin-containing islets. This hyperexpression did not correlate with detectable upregulation of the transcriptional regulator NLRC5. However, it was strongly associated with increased STAT1 expression in all three cohorts. Islet hyperexpression of HLA class I molecules occurred in the insulin-containing islets of patients with recent-onset type 1 diabetes and was also detectable in many patients with disease duration of up to 11 years, declining thereafter. CONCLUSIONS/INTERPRETATION: Islet cell HLA class I hyperexpression is not an artefact, but is a hallmark in the immunopathogenesis of type 1 diabetes. The response is closely associated with elevated expression of STAT1 and, together, these occur uniquely in patients with type 1 diabetes, thereby contributing to their selective susceptibility to autoimmune-mediated destruction. | en_GB |
dc.description.sponsorship | We are pleased to acknowledge financial support from the European Union's Seventh
Framework Programme PEVNET [FP7/2007-2013] under grant agreement number 261441.
The participants of the PEVNET consortium are described at
http://www.uta.fi/med/pevnet/publications.html. Additional support was from a Diabetes
Research Wellness Foundation Non-Clinical Research Fellowship and, since 2014, a JDRF
Career Development Award (5-CDA-2014-221-A-N) to S.J.R. KDJ has received grants from
the South-Eastern Norway Regional Health Authority, the Novo Nordisk Foundation and
through the PEVNET Consortium. The research was also performed with the support of the
Network for Pancreatic Organ Donors with Diabetes (nPOD), a collaborative type 1 diabetes
research project sponsored by the Juvenile Diabetes Research Foundation International (JDRF,
JDRF 25-2013-268 to M.A.; including a subcontract to J.S.K.) and with a JDRF research grants
awarded to the nPOD-V consortium (JDRF 25-2012-516 to A.P. and JDRF 25-2012-770 to
M.A). Additional funding was provided by JDRF to C.E.M (JDRF 47-2013-520) and from
National Institute of Health (UC4 DK104155) to I.C.G and (R01 AI092453) to M.v.H. | en_GB |
dc.identifier.doi | 10.1007/s00125-016-4067-4 | |
dc.identifier.uri | http://hdl.handle.net/10871/23027 | |
dc.language.iso | en | en_GB |
dc.publisher | Springer Verlag | en_GB |
dc.relation.url | http://www.ncbi.nlm.nih.gov/pubmed/27506584 | en_GB |
dc.rights | This is the author accepted manuscript. The final version is available from Springer via the DOI in this record. | en_GB |
dc.subject | DiViD | en_GB |
dc.subject | HLA class I | en_GB |
dc.subject | HLA-F | en_GB |
dc.subject | Islet cell | en_GB |
dc.subject | Pancreas | en_GB |
dc.subject | STAT1 | en_GB |
dc.subject | Type 1 diabetes | en_GB |
dc.subject | nPOD | en_GB |
dc.title | Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes. | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2016-08-16T11:00:23Z | |
dc.identifier.issn | 0012-186X | |
dc.identifier.journal | Diabetologia | en_GB |